FDA Rejects Aldeyra’s Dry Eye Drug, Cites Need for Additional Trial

The FDA on Monday rejected Aldeyra Therapeutics’ investigational reactive aldehyde species modulator reproxalap, which the company is proposing as a treatment for dry eye disease.